公开(公告)号：US09593095B2

公开(公告)日：2017-03-14

申请号：US14305649

申请日：2014-06-16

Applicant: Duke University ,  The University of Kansas ,  Southern Research Institute

Inventor： Patrick C. Seed ,  Carlos C. Goller ,  Steven Rogers ,  Brooks Maki ,  Frank Schoenen ,  James Noah ,  E. Lucile White

IPC: A61K31/381 ,  C07D333/24 ,  C07D417/12 ,  A61K31/4439 ,  A61K31/43 ,  A61K31/545 ,  C07D409/12 ,  C12Q1/02

CPC classification number: C07D333/24 ,  A61K31/381 ,  A61K31/43 ,  A61K31/4439 ,  A61K31/545 ,  C07D409/12 ,  C07D417/12 ,  C12Q1/025 ,  Y02A50/47 ,  Y02A50/473 ,  Y02A50/478 ,  Y02A50/481

Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.

Abstract translation: 本发明一般涉及抑制，预防或治疗细菌感染的方法的发现。 本发明还涉及抑制细菌性胶囊生物发生的方法。

公开(公告)号：US09464035B2

公开(公告)日：2016-10-11

申请号：US14388494

申请日：2013-03-15

Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human Services ,  The University of Kansas

Inventor： Juan Jose Marugan ,  Wei Zheng ,  Samarjit Patnaik ,  Noel Southall ,  Ellen Sidransky ,  Ehud Goldin ,  Wendy Westbroek ,  Elma Aflaki ,  Steven Andrew Rogers ,  Frank John Schoenen

IPC: C07C235/64 ,  C07C235/60 ,  C07C237/22

CPC classification number: C07C235/64 ,  C07B2200/07 ,  C07C235/60 ,  C07C237/22

Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.

公开(公告)号：US20160289217A1

公开(公告)日：2016-10-06

申请号：US15035610

申请日：2014-11-11

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Brian S.J. BLAGG ,  Huiping ZHAO

IPC: C07D405/12 ,  A61K45/06 ,  C07D405/14 ,  G06F19/00 ,  A61K31/496 ,  A61K31/5377 ,  C07D311/16 ,  A61K31/352 ,  A61K31/453 ,  A61K31/4025

CPC classification number: C07D405/12 ,  A61K31/352 ,  A61K31/4025 ,  A61K31/453 ,  A61K31/496 ,  A61K31/5377 ,  A61K45/06 ,  C07D311/16 ,  C07D405/14 ,  C07D413/12 ,  G06F19/00 ,  G16H50/50

Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.

公开(公告)号：US20130123296A1

公开(公告)日：2013-05-16

申请号：US13732965

申请日：2013-01-02

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Ingrid Gunda Georg ,  Joseph S. Tash ,  Ramappa Chakrasali ,  Sudhakar Rao Jakkaraj ,  Katherine Roby

IPC: C07D471/04 ,  C07D231/56

CPC classification number: C07D471/04 ,  A61K31/416 ,  A61K31/4162 ,  C07D231/56

Abstract: Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject.

Abstract translation: 生育能力管理可以包括：向受试者施用一种或多种剂量的式I化合物，以降低受试者的生育能力。 生育能力管理还可以包括给予有效量的化合物以损害男性受试者的Sertoli细胞功能; 抑制受试者的精子发生; 减少受试者的睾丸重量; 减少女性受试者的卵巢重量; 减少女性受试者的血清孕酮; 影响女性卵巢卵泡功能; 导致受试者的可逆生育力。 为了返回生育力，该方法可以包括停止对受试者施用化合物以使受试者的生育力恢复。 该化合物可被用于不可逆地灭菌受试者。

公开(公告)号：US11891668B2

公开(公告)日：2024-02-06

申请号：US17514724

申请日：2021-10-29

Applicant: The University of Kansas ,  Kansas State University Research Foundation

Inventor： Mei He

IPC: A61K47/00 ,  C12Q1/6886 ,  A61K47/69 ,  G01N33/574 ,  G01N33/543 ,  B03C1/015 ,  B03C1/30 ,  B01L3/00 ,  A61K49/00

CPC classification number: C12Q1/6886 ,  A61K47/6901 ,  A61K49/0097 ,  B01L3/502715 ,  B01L3/502761 ,  B03C1/015 ,  B03C1/30 ,  G01N33/5434 ,  G01N33/54333 ,  G01N33/574 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2446/80

Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

公开(公告)号：US11634404B2

公开(公告)日：2023-04-25

申请号：US16093365

申请日：2017-04-14

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services ,  The University of Kansas ,  The University of North Carolina at Chapel Hill

Inventor： David R. Sibley ,  Amy Elizabeth Moritz ,  R. Benjamin Free ,  Joseph P. Steiner ,  Noel Terrence Southall ,  Marc Ferrer ,  Xin Hu ,  Warren S. Weiner ,  Jeffrey Aubé ,  Kevin Frankowski

IPC: C07D401/12 ,  A61P25/28 ,  C07D295/185 ,  C07D209/42 ,  C07D213/65 ,  C07D213/81 ,  C07D235/24 ,  C07D307/85 ,  C07D317/64 ,  C07D333/70 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

公开(公告)号：US20220283058A1

公开(公告)日：2022-09-08

申请号：US17633421

申请日：2020-08-06

Applicant: THE UNIVERSITY OF KANSAS

Inventor： Eduardo ROSA-MOLINAR ,  Allen HASE ,  Robert YOUNG ,  Christian HORNHUBER

IPC: G01N1/06 ,  G01N1/28 ,  H01J37/20

Abstract: A plurality of accessory components for use in respective reel to reel sectioning, serial sectioning, and array tomography sectioning described herein incorporate mechanical and electro-mechanical engineering to provide accessory tools for attachment to and use with a microtome, as shown in several of the figures of this disclosure.

公开(公告)号：US10654807B2

公开(公告)日：2020-05-19

申请号：US15106488

申请日：2014-12-19

Applicant: The University Of Kansas

Inventor： Sunil Abraham David ,  Hari Prasad Kokatla ,  Diptesh Sil ,  Subbalakshmi Malladi ,  Lauren Miranda Fox

IPC: C07D215/38 ,  A61K31/47 ,  A61K39/39 ,  A61K39/00

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

公开(公告)号：US10399964B2

公开(公告)日：2019-09-03

申请号：US15940152

申请日：2018-03-29

Applicant: The University of Kansas

Inventor： Blake R. Peterson

IPC: C07D407/12 ,  A61P35/00 ,  G01N33/58

Abstract: A compound can be a fluorescent taxane derivative having a structure of Formula 1, salt, stereoisomer, tautomer, polymorph, or solvate thereof. Formula 1 can be defined as: L, L-NH, or L-NH—C═O is a linker; and R is a substituent, where —OH, —O−, —NH2, and NH—CH3 are examples. Examples of linkers can include glycine, beta-alanine, gamma-aminobutyric acid (GABA). Pharmaceutical compositions can include the compound and a pharmaceutically acceptable carrier, and may be configured for intravenous injection. The fluorescent taxane derivative can be used to treat cancer and non-cancer diseases. The fluorescent taxane derivative can be used to monitor cellular efflux and determine whether a cell will efflux paclitaxel.

公开(公告)号：US20190169487A1

公开(公告)日：2019-06-06

申请号：US16270144

申请日：2019-02-07

Applicant: THE UNIVERSITY OF KANSAS

Inventor： REZA BARATI GHAHFAROKHI

IPC: C09K8/594 ,  C09K8/584 ,  C09K8/588 ,  E21B43/24 ,  E21B43/16

Abstract: Polyelectrolyte nanoparticles are generated to stabilize foam for use in enhanced oil recovery. Stability is further enhanced by optimizing pH and a ratio of polycationic and polyanioinic materials, resulting in stronger and longer lasting foams in the presence of crude oil. Use of these nanoparticles results in negligible damage to formation permeability.